Human brain effects of DMT assessed via EEG-fMRI
In a within-subject, placebo-controlled EEG–fMRI study of 20 volunteers, IV DMT produced robust increases in global functional connectivity, network disintegration and desegregation, and a compression of the principal cortical gradient. These imaging changes tracked subjective intensity, correlated with PET-derived 5‑HT2A receptor maps and EEG alterations, supporting a predominant action of DMT on the transmodal association cortex rich in 5‑HT2A expression.
Abstract
Psychedelics have attracted medical interest, but their effects on human brain function are incompletely understood. In a comprehensive, within-subjects, placebo-controlled design, we acquired multimodal neuroimaging [i.e., EEG-fMRI (electroencephalography-functional MRI)] data to assess the effects of intravenous (IV) N,N-Dimethyltryptamine (DMT) on brain function in 20 healthy volunteers. Simultaneous EEG-fMRI was acquired prior to, during, and after a bolus IV administration of 20 mg DMT, and, separately, placebo. At dosages consistent with the present study, DMT, a serotonin 2A receptor (5-HT2AR) agonist, induces a deeply immersive and radically altered state of consciousness. DMT is thus a useful research tool for probing the neural correlates of conscious experience. Here, fMRI results revealed robust increases in global functional connectivity (GFC), network disintegration and desegregation, and a compression of the principal cortical gradient under DMT. GFC × subjective intensity maps correlated with independent positron emission tomography (PET)-derived 5-HT2AR maps, and both overlapped with meta-analytical data implying human-specific psychological functions. Changes in major EEG-measured neurophysiological properties correlated with specific changes in various fMRI metrics, enriching our understanding of the neural basis of DMT’s effects. The present findings advance on previous work by confirming a predominant action of DMT—and likely other 5-HT2AR agonist psychedelics—on the brain’s transmodal association pole, i.e., the neurodevelopmentally and evolutionarily recent cortex that is associated with species-specific psychological advancements, and high expression of 5-HT2A receptors.
Research Summary of 'Human brain effects of DMT assessed via EEG-fMRI'
Introduction
Earlier neuroimaging work on classic psychedelics has converged on a picture of disrupted large-scale cortical organisation, commonly implicating the brain's transmodal association cortex pole (TOP) at the upper end of a principal sensorimotor-to-association gradient. The TOP is linked to high-level cognitive functions, prolonged temporal integration, and expanded cortical development in primates, and prior studies suggest that psychedelic subjective effects reflect dysregulation of these association cortices with possible disinhibition of evolutionarily earlier systems such as limbic circuitry. However, most prior human work has treated electrophysiological and haemodynamic measures separately, which limits the ability to directly relate neuronal activity to fMRI-derived connectivity changes and leaves open concerns about vascular confounds. Timmermann and colleagues set out to address these gaps by performing simultaneous electroencephalography (EEG) and functional MRI (fMRI) in healthy volunteers during eyes-closed resting state, administering intravenous DMT (20 mg) versus placebo in a within-subject, counterbalanced design. The study aimed to characterise static and dynamic effects of DMT on spectral EEG metrics (power bands, signal diversity, travelling waves), on fMRI measures (within- and between-network connectivity, global functional connectivity, pairwise connectivity, and the brain's principal cortical gradient), and to link these multimodal changes to subjective intensity, plasma DMT levels, and an independent in vivo 5-HT2A receptor density map.
Methods
This single-blind, placebo-controlled, counterbalanced within-subjects study recruited 20 participants (mean age 33.5 y, SD = 7.9; 7 female). Each volunteer completed two scanning days separated by two weeks. On each day participants underwent a 28-min resting-state fMRI/EEG session with intravenous injection at the end of minute 8 of either 10 mL saline (placebo) or 20 mg DMT in fumarate form (dissolved in 10 mL saline), injected over 30 s and flushed with 10 mL saline. Eyes were closed throughout and an eye mask prevented opening. In a separate scan run (not the primary resting recording reported here) participants provided minute-by-minute verbal intensity ratings; these real-time ratings and previously measured DMT plasma concentrations were used as regressors for dynamic analyses. fMRI acquisition used a 3T scanner (TR = 2000 ms, voxel 3 × 3 × 3 mm3) and preprocessing followed an established pipeline (despiking, slice time and motion correction, brain extraction, registration to MNI space, scrubbing with FD threshold 0.4, spatial smoothing, band-pass filtering 0.01–0.08 Hz, detrending, nuisance regression including ventricles, draining veins and local white matter). Four participants were excluded from group fMRI analyses for excessive motion (>20% scrubbed volumes); additional subsample analyses used more stringent motion thresholds. EEG was recorded concurrently from 31 channels with MR-compatible equipment, sampled at 5 kHz and preprocessed to remove gradient and ballistocardiogram artefacts, downsampled to 250 Hz, band-pass filtered and epoched. Two participants were removed from EEG analyses for excessive artefacts and one was excluded from alpha analyses due to an atypical alpha peak; joint EEG–fMRI analyses included 12 participants who survived both modalities' preprocessing. Analyses: For fMRI, static resting-state functional connectivity (sRSFC) was assessed using ICA-derived canonical resting-state networks and dual regression to estimate within-network integrity, between-network segregation, and regional/global functional connectivity (GFC) across 112 parcellated regions (100 cortical from Schaefer atlas plus 12 subcortical). Dynamic resting-state FC (dRSFC) used tapered sliding windows (44 s, 2-s step) and related timecourses of GFC and pairwise FC to minute-by-minute intensity ratings using linear mixed-effects models, with FDR correction for multiple comparisons; analogous analyses were performed using average plasma DMT levels. Principal cortical gradients were obtained using diffusion map embedding on interregional FC similarity matrices, followed by Procrustes alignment. EEG analyses included spectral decomposition isolating oscillatory from 1/f components, band definitions (delta 1–4 Hz, theta 4–8 Hz, alpha 8–13 Hz, beta 13–30 Hz, gamma 30–45 Hz), cluster-based permutation testing, Lempel–Ziv complexity (LZs per channel, averaged as LZc) for signal diversity, and quantification of cortical travelling waves via 2D FFTs on midline electrodes. EEG–fMRI relationships were assessed by convolving EEG metrics with a canonical haemodynamic response function and relating them to region-wise GFC and pairwise FC timecourses using linear mixed-effects models. An independent in vivo 5-HT2A receptor density map from prior PET work was used to test spatial overlap with dynamic GFC effects, and NeuroSynth meta-analytic maps were used to characterise associated functions.
Results
Samples and exclusions: 20 participants completed the protocol. Four subjects were excluded from the core fMRI group analyses for excessive motion, yielding analyses based on 16 participants for many fMRI contrasts (consistent with reported t tests). EEG preprocessing resulted in further exclusions, and joint EEG–fMRI analyses were performed on n = 12 participants who met both modalities' quality thresholds. Static fMRI connectivity: Averaged over the 8-min postinjection peak window, DMT decreased within-network integrity across canonical resting-state networks (P < 0.05, FDR corrected) with the exception of the salience (SAL) and limbic (LIM) networks. In contrast, DMT increased global functional connectivity (GFC) in the SAL, frontoparietal control (FP), and default-mode (DMN) networks (P < 0.05, FDR corrected). Between-network segregation was reduced, especially involving FP, SAL and DMN (P < 0.05, FDR corrected). Region-level GFC increases were observed in medial prefrontal cortex, dorsolateral PFC, insula and temporoparietal junction, and whole-brain average GFC increased under DMT compared with placebo [t(15) = 3.11, P = 0.007, 95% CI = 0.028 to 0.15]. Motion-control subsample analyses and global signal regression (GSR) checks yielded broadly consistent patterns. Dynamic fMRI connectivity: Using sliding-window dRSFC related to real-time intensity ratings, increases in GFC of DMN, FP, SAL and LIM networks correlated positively with intensity (P < 0.05, FDR corrected). Pairwise connectivity showed widespread positive associations with intensity, but negative associations were found between intensity and pairwise connectivity of visual–somatomotor/subcortical links (P < 0.05, FDR corrected). Time-resolved results indicated maximal increases in DMN and FP GFC during roughly minutes 1–6 postinjection (P < 0.05, cluster corrected); pairwise connectivity rose broadly in the first minute whereas segregation between lower-order unimodal sensory and motor areas became more apparent from minute two onward. Dynamic GFC changes also correlated with average plasma DMT concentrations. Spatial overlap analyses showed that regions with higher 5-HT2A receptor density related positively to the GFC model involving intensity ratings, and NeuroSynth decoding of GFC and 5-HT2A maps highlighted high-level cognitive and linguistic terms (e.g., language, semantic). Principal cortical gradient: Gradient-mapping revealed a compression of the principal sensorimotor-to-association axis under DMT. High-order TOP regions exhibited reduced gradient scores (movement toward zero) while low-level unimodal regions showed increased gradient scores toward zero, indicating reduced differentiation between unimodal and transmodal cortex. Network-wise, gradient scores increased within unimodal sensory networks (SM, VIS) and DAN, and decreased within FP, DMN and LIM, consistent with diminished macroscale hierarchical organisation. EEG spectral and complexity results: Time-averaged EEG over the 8-min postinjection window showed widespread decreases in alpha power (P < 0.01, cluster corrected) and increases in delta (P < 0.05) and gamma power (P < 0.01). Signal diversity (Lempel–Ziv complexity: LZs per channel and global LZc) increased significantly under DMT (P < 0.01). Dynamic correlations with real-time intensity indicated that greater intensity co-occurred with larger increases in delta power and LZc, and greater decreases in global alpha and posterior beta power (P < 0.05). Temporally resolved analyses found alpha reductions approximately 0–8 min (P = 0.001, cluster corrected), LZc increases ~2–14 min (P = 0.001), and delta increases largely confined to the onset phase ~0–4 min (P = 0.006). A modest beta reduction was observed in the first minute (P = 0.04). Forward travelling-wave power increased while backward wave power decreased. Subjective ratings of the richness of conscious experience correlated with LZc (r = 0.7, P = 0.008). EEG–fMRI relationships: Using simultaneous data (n = 12), frontal delta power increases related positively to widespread regional GFC increases across frontal, temporal, parietal, motor and visual association cortices (P < 0.05, FDR corrected), a result echoed in pairwise FC. Parietal alpha decreases were negatively associated with GFC increases in TOP networks and regions, and alpha reductions were linked to decreased visual–somatomotor coupling but increased coupling between sensory and TOP regions. Occipital gamma increases associated with GFC increases in FP regions and the LIM network (P < 0.05), and LZc increases associated with GFC increases in TOP and LIM (P < 0.05). These modality-crossing associations were detectable using within-subject timecourse models, whereas simple between-subject averaging reduced these effects. Other observations and validation: The authors report that head motion was significantly greater under DMT than placebo, but subsample analyses controlling for motion produced consistent results. GSR and other preprocessing checks are reported in supplementary material. The study found few robust correlations between imaging metrics and specific phenomenological features (e.g., entity encounters), suggesting limited mapping of particular subjective elements to distinct neural measures in this dataset.
Discussion
Combining EEG and fMRI in a single simultaneous protocol, the study presents convergent evidence that DMT induces a multilevel dysregulation of high-order cortex consistent with a global brain action of classic psychedelics. The authors interpret the principal findings—network disintegration and desegregation, decreased alpha power, increased signal diversity and gamma power, altered travelling waves, increased delta power, elevated global functional connectivity, and a compression of the principal cortical gradient—as pointing to reduced segregation of the TOP from the rest of cortex and a collapse of the brain's hierarchical organisation. They argue that regions most affected spatially overlap with areas of dense 5-HT2A receptor expression and with neuroimaging maps related to high-level cognitive and linguistic functions, supporting a model in which 5-HT2A receptor agonism causally contributes to the observed functional effects. The authors relate increased signal entropy and hyperconnectivity to the entropic brain hypothesis, with LZc increases correlating with reported richness of experience. Delta power increases correlated with elevated global connectivity and are discussed as a marker of profound alteration of conscious content rather than merely reduced level of consciousness. Observations linking alpha reductions, gamma increases and entropy enhancements with limbic GFC increases are taken as consistent with limbic disinhibition hypotheses relevant to memory and emotion processing. Timmermann and colleagues note limitations that temper interpretation. The study is exclusive to DMT without an active drug control, leaving questions about specificity compared with other classic psychedelics. Head motion was larger under DMT, and although subsample analyses and preprocessing checks were used to validate results, the authors acknowledge that fMRI connectivity metrics remain sensitive to motion and call for larger datasets with equivalent motion between conditions. They also discuss potential confounds with arousal; while some imaging effects could be compatible with increased arousal, the spatial and temporal patterning (including delta increases and gradient compression) exceed what would be expected from arousal alone, and drowsiness ratings did not convincingly account for the observed effects. Finally, the authors observe relatively few robust links between imaging metrics and fine-grained subjective features and recommend future neurophenomenological work with richer within-subject sampling and larger datasets. In their concluding interpretation, the authors consolidate the view that DMT principally targets developmentally and evolutionarily recent transmodal cortex, increasing its communication with the rest of the brain and producing a hyperassociative, higher-entropy mode of processing. They suggest these global neural changes may relate to plasticity and to alterations in human-specific psychological faculties, while emphasising that such implications remain to be tested in future research.
View full paper sections
METHODS
Participants and Experimental Procedures. This was a single-blind, placebo-controlled, counter-balanced design. An initial visit at the Imperial College Research Facility was focused on assessing physical and mental health to ensure suitability. Exclusion criteria included: <18 y old at the moment of participation, MR contraindications, absence of experience with a psychedelic, an adverse reaction to a psychedelic, history of psychiatric or physical illness rendering unsuitable for participation (i.e., diabetes, epilepsy, or heart disease), family history of psychotic disorder, or excessive use of alcohol or drugs of abuse. All participants provided written informed consent for participation in the study. This study was approved by the National Research Ethics Committee London-Brent and the Health Research Authority and was conducted under the guidelines of the revised Declaration of Helsinki (), the International Committee on Harmonization Good Clinical Practices guidelines, and the National Health Service Research Governance Framework. Imperial College London sponsored the research, which was conducted under a Home Office license for research with Schedule 1 drugs. Volunteers participated in two testing days at the Imperial College Clinical Imaging Facility, separated by two weeks. On each testing day, participants arrived and were tested for drugs of abuse and were involved in two separate scanning sessions. In this initial session (task free), they received intravenous (IV) administration of either placebo (10 mL of sterile saline) or 20 mg DMT (in fumarate form dissolved in 10 mL of sterile saline)-injected over 30 s, and then flushed with 10 mL of saline over 15 s-in a counter-balanced order (half of the participants received placebo and the other half received DMT). This first session always consisted of continuous resting-state scans which lasted 28 min with DMT/placebo administered at the end of 8th min and scanning was over 20 min after injection. Participants laid in the scanner with their eyes closed (an eye mask was used to prevent eyes opening), while EEG activity was recorded. Following the scanning procedure, participants were interviewed and completed questionnaires designed to assess the subjective effects experienced during the scan [Visual Analog Scales and validated scales: 11 Dimensions Altered States of Consciousness Questionnaire-ASC-11D (69) and the Mystical Experience Questionnaire-MEQ-30]. A second session then followed with the same procedure as the initial session (including scanning conditions), except on this occasion participants were (audio) cued to verbally rate the subjective intensity of drug effects every minute in real time while in the scanner. These ratings were then used for analysis in the present report. This article reports the results concerning the resting-state scans in which no intensity ratings were asked, while using intensity ratings collected in other (nonanalyzed) scan runs as covariates for dynamic fMRI and EEG analysis. In total, 20 participants completed all study visits (7 female, mean age = 33.5 y, SD = 7.9). fMRI and EEG Acquisition. Images were acquired in a 3T MR scanner (Siemens Magnetom Verio syngo MR B17) using a 12-channel head coil for compatibility with EEG acquisition. Functional imaging was performed using a T2*-weighted BOLDsensitive gradient echo planar imaging sequence [repetition time (TR) = 2000ms, echo time (TE) = 30 ms, acquisition time (TA) = 28.06 mins, flip angle (FA) = 80°, voxel size = 3.0 × 3.0 × 3.0mm3, 35 slices, interslice distance = 0 mm]. Wholebrain T1-weighted structural images were also acquired. EEG was recorded inside the MRI environment during image acquisition. EEG data were recorded at 31 scalp sites following the 10 to 20 convention with an MR-compatible BrainAmp MR amplifier (BrainProducts, Munich, Germany) and an MR-compatible cap (BrainCap MR; BrainProducts GmbH, Munich, Germany). This system referenced all electrodes to FCz and AFz served as ground electrode. We additionally recorded with two additional ECG channels to improve heart rate acquisition for artifact minimization during EEG preprocessing, and all impedances were kept below 20kΩ. EEG was sampled at 5 kHz and with a hardware 250 Hz low-pass filter. EEG-MR clock synchronization was ensured using the Brain Products SyncBox hardware. Additional recordings of 5 min eyes-closed resting-state were performed outside of the scanner before DMT/placebo was administered in order to determine the profile of EEG activity in the time and frequency domain and ensure that artifact minimization procedures achieved a similar profile. fMRI Preprocessing. The same preprocessing pipeline as used in previous work with LSDwas used here. Four out of 20 participants were discarded from group analyses due to excessive head movement during the 8-min post DMT timeperiod shown in Fig.[>20% of scrubbed volumes with a scrubbing threshold of frame-wise displacement (FD) of 0.4]. Three further participants were removed for dynamic analysis after reaching a 20% threshold for total amount of scrubbed volumes for the full 28 min of scanning. Preprocessing steps consisted of 1) despiking [3dDespike, Analysis of Functional NeuroImages (AFNI) (73)]; 2) slice time correction [3dTshift, AFNI (73)]; 3) motion correction [3dvolreg, AFNI] by registering each volume to the most similar volume, in the least squares sense, to all others (in-house code); 4) brain extraction [BET, FSL (74)]; 5) rigid body registration to anatomical scans; 6) nonlinear registration to 2mm MNI brain [Symmetric Normalization, Advanced Normalization Tools (ANTS) (75)]; 7) scrubbing-using an FD threshold of 0.4 and scrubbed volumes were replaced with the mean of the surrounding volumes. Additional preprocessing steps included: 8) spatial smoothing (FWHM) of 6 mm [3dBlurInMask, AFNI (73)]; 9) band-pass filtering between 0.01 and 0.08 Hz [3dFourier, AFNI (73)]; 10) linear and quadratic detrending [3dDetrend, AFNI (73)]; 11) regressing out nine nuisance regressors [all nuisance regressors were band-pass filtered with the same filter as in step 9: out of these, 6 were motion related (3 translations, 3 rotations) and 3 were anatomically related (not smoothed). Specifically, the anatomical nuisance regressors were: a) ventricles [Freesurfer, eroded in 2 mm space], b) draining veins (DVs) [FSL's CSF minus Freesurfer's Ventricles, eroded in 1 mm space], and c) local white matter (WM) [FSL's WM minus Freesurfer's subcortical gray matter structures, eroded in 2 mm space]. Regarding local WM regression, AFNI's 3dLocalstatwas used to calculate the mean local WM time-series for each voxel, using a 25 mm radius sphere centered on each voxel]. Values related to head motion (i.e., frame-wise displacement; FD) were significantly different between DMT and placebo (P = 0.003). While we employed significant motion correction methods, our findings could still be influenced by motion. To further validate the robustness of these findings, additional analyses were carried out using a subsample of eight participants showing no relationship between motion and connectivity using the same threshold for exclusion (FD = 0.4). This first subsample was identified by recursively removing participants until the correlation between Euclidian node distance and motion vs functional connectivity was no longer significant for the DMT condition (SI Appendix, Fig.). A second subsample was identified by using a stringent method of exclusion from analysis of FD = 0.2 (SI Appendix, Fig.), which resulted in only 3 participants. The results were broadly replicated in both analyses (SI Appendix, Figs.and). EEG Preprocessing. Gradient artifacts (GA) caused by the fMRI were removed using an average artifact template subtraction (AAS) algorithm which is part of the BrainVision Analyser software. The algorithm computes a representative template artifact based on a sliding average of 21 TR windows which is then subtracted from each TR window, thereby removing most of the MR-related noise. Following gradient artifact correction, the data were downsampled to 250 Hz and ballistocardiogram (BCG) artifacts were reduced by placing heartbeat markers corresponding to the R-peak determined on a representative template of the signal corresponding to the ECG channels (low-pass filtered at 15 Hz). An AAS algorithm was used to correct for the pulse artifact by producing a template resulting from averaging multiple cardiac cycles using a sliding-window approach, generating a different template for each sliding window, which is subtracted from that period. The following preprocessing steps were performed using the Fieldtrip software (79): The data were demeaned, band-pass filtered at 1 to 45 Hz, and epoched in separate 2-s trials. The data were then visually inspected and trials containing artifacts associated with jaw clenches and gross artifacts were removed. Independent component analyses were subsequently performed to remove residual BCG and GA artifacts as well as eye movements. If remaining gross artifacts were observed, the corresponding segments of the data were removed and ICA was ran again for improved results. Validation of preprocessing results was performed by comparing out-of-scanner EEG profile in the time and frequency domain, as well as in-scanner data. Two out of the 20 subjects were removed due to excessive data artifacts. Furthermore, as alpha analyses were performed on a fixed 8 to 13 Hz window, one subject exhibiting pnas.org an alpha peak at 7.5 Hz was removed from group analyses as alpha analyses were performed on a fixed 8 to 13 Hz window. Participants where we had to discard (due to artifacts) 25% of the initial 8 min of data post DMT/placebo injection were removed from main EEG results presented in Fig.. No further participants reached the 25% threshold when considering the full 28-min scan. Compared with the fMRI data, a higher threshold of exclusion was used for the EEG, as this is convention, due to the higher temporal resolution and signal-to-noise ratio with EEG. EEG-fMRI analysis was conducted only for those participants who survived both the fMRI and EEG thresholds for exclusion (n = 12) (71).
CONCLUSION
Utilizing two complementary imaging modalities performed in tandem (EEG-fMRI), the present study offers an advanced view of the acute action of a psychedelic on the human brain. Its results provide an update on the current thinking regarding the neural correlates of the psychedelic state, consolidating some relatively well-established properties-such as network disintegration and desegregation, decreased alpha power and increased spontaneous signal complexity or entropy, as well as relationships between metrics-but also strengthening confidence in some more recent observations-such as altered traveling wavesand increased deltaand gamma power, and global functional connectivity (GFC). Perhaps, the most enlightening aspect of the present results, however, is how they converge on a global brain action of psychedelics, implicating dysregulation of activity in the brain's transmodal association cortex pole (TOP). While decreased communication between low-level sensorimotor modules at the lower end of the cortex's principal organizational gradient was also seen, dynamic and time-resolved analyses suggested that these effects may occur subsequent in time to a primary action at the brain's TOP. Psychedelics are particularly useful research tools for studying the neurobiology of consciousness. Their ability to shift its quality in a fundamental and often enduringly transformative way, while preserving wakefulness, is arguably unparalleled in pharmacology. We believe the present results, and particularly those pertaining to whole-brain organization, such as global FC, pairwise FC, and the principal FC gradient, now point toward a signature global brain action of psychedelics that is robust, reliable, unique, and revealing, not just of "psychedelic consciousness" but of conscious experience more broadly. A wealth and diversity of convergent data is now highlighting the human cortex's principal functional gradient, spanning from a lower-order sensorimotor cortex pole to a higher-order transmodal association cortex pole, as a defining organizational dimension of the human brain. Covering all the relevant properties that match this principal gradient, dimension, or axis, is beyond the scope of the present paper, but some important examples include: primate to human cortical expansion; ontogenetic cortical expansion; various aspects of developmental maturation -including prolonged plasticity periods, myelination degree, metabolism and blood flow, excitatory neurotransmission (29); serotonin 2A receptor expression; the degree of abstractionand temporal duration (44) of information processing [see Sydnor et al.for a review]; and traveling waves linked to infraslow cycles of arousal. The present study is not the first to apply whole-brain metrics to psychedelic neuroimaging data and show their relationship to signature aspects of the psychedelic experience, and neither is it the first to propose that a profound whole-brain action may differentiate classic psychedelics from analogous compounds such as MDMA; however, it addresses the global brain action of a psychedelic in a comprehensive multivariate and multimodal way, twinned with an especially immersive psychedelic experience. The picture that emerges is one of a drug-induced collapse of the defining principal gradient of the brain, such that its transmodal association cortex pole becomes less segregated from-or more integrated with-the rest of the cortex. The TOP is, per definition, transmodal in nature and evolutionarily "new" or recent, whereas the lower-order cortex is unimodal and older. That in vivo PET maps of 5-HT2A receptor distribution overlap with the principal functional gradient, as well as the global FC effects of psychedelics (Fig.), implies that psychedelic-induced increases in 5-HT2AR signaling are causal of the relevant functional effects; an assumption backed by computational modeling. In the present study, we found that dysregulation of brain activity (e.g., indexed via reductions of alpha power, as well as by increases in gamma power and signal diversity) was associated with increased global functional connectivity at the brain's TOP. These findings are indicative of a transition to a more entropic mode of brain functioning under psychedelics which may account for their distinct phenomenology. We also found increases in (frontal) delta power following DMT; these increases were correlated with a state of increased global connectivity (fMRI), consistent with the notion that increased delta may serve as a marker for a significant alteration of consciousness, rather than one exclusively linked to reduced conscious level-as traditionally thought. Simultaneously, we found that alpha power reductions, gamma power increases, and signal entropy enhancements were related to higher GFC in the limbic network (Fig.), consistent with the hypothesis that the emergence of psychedelic phenomena may involve limbic disinhibition, with implications for memory and emotion processing. Broadly, these findings converge on the notion that DMT-induced-5-HT2AR agonism dysregulates high-level cortical activity and limbic activity. There are plentiful theories on the uniqueness of the human brain, mind, and behavior-e.g., seepnas.org semantic and linguistic domains -is one candidate. It may be telling therefore that both the GFC × intensity and 5-HT2A receptor spatial maps overlapped with NeuroSynth functional terms related to cognitive faculties that have evolved greatly in our species, e.g., "language" and "semantic." Recent findings suggest that 5-HT2AR signaling plays a direct, receptor and species selective role in early phases of cortical expansion, e.g., increasing the proliferation of basal progenitor cells. This raises the possibility that the key target of psychedelics-the 5-HT2A receptor-has played some causal role in the expansion of the human cortex. The abundance of cortical neurons, particularly in the TOP of the cortex [20-fold increase from macaque to human (50)], is a defining feature of the human brain. The densest expression of 5-HT2A receptors can be found in the TOP of the cortex, and, as the present study has shown, this is also where psychedelics have their initial and most robust effects. Increased synaptic growth via 5-HT2AR agonismimplicates the receptor in ontogenetic brain development and learning. Indeed, there is now a wealth of evidence linking 5-HT2AR signaling with the induction of various aspects of neural and behavioral plasticity, but whether such effects are functionally advantageous or impairing is a complex question dependent on several factors. Relatedly, the acute and longer-term psychological effects of psychedelics are thought to be highly context sensitive and dependent, explaining why such emphasis is placed on "set and setting" in psychedelic therapy. It is important to note that 5-HT2AR is also densely expressed in the primary visual cortex (SI Appendix, Fig.), and DMT is known for inducing vivid visual imagery. Further studies are required to examine the specific DMTinduced increased connectivity we found between the TOP of the cortex and visual areas (Fig.and), which may help explain the visual quality of the DMT experience. The question of what is specific to the action of DMT versus other classic psychedelics is difficult to answer from the present study alone, with its exclusive focus on DMT and lack of an active drug control condition. Most of this study's findings are consistent with previous observations on psychedelic neuroimaging data, albeit with a higher fidelity and multilevel depth-afforded by the study's design and the subjective potency of 20 mg of I.V. DMT. Increased delta power may be DMT specific, but more research is needed to test this (e.g., see refs.. With regard to other drugs and states, the pattern and quality of effects seen here with DMT and EEG-fMRI are quite distinct from those seen previously with a serotonin reuptake inhibitor, stimulant, sedative, dissociative[although see], as well as MDMA. It is intriguing to speculate that increased global functional connectivity in highlevel regions and networks may be a somewhat exclusive property of the action of classic psychedelics. However, a broadly similar profile of brain function (i.e., dysregulation of activity in high-level cortex and compression of the brain's hierarchical organization) has been seen in experienced meditators meditating (61)-as well as in schizophrenia,and infancy. Importantly, validation checks were performed to assess the influence of motion confounds, as well as global signal regression (GSR). Relevant results can be found in the SI Appendix, Figs. S2-S5, S8, and S10. Previous psychedelic GFC results have been publishedthat have shown different patterns of change than those observed here with DMT and previously with LSD and psilocybin (25)-although a recent independent study with psilocybin reported broadly convergent results with our own. One potentially important difference in these studies' analytical approaches is whether or not they performed GSR. Due to assumptions that the global signal contains functionally meaningful neuronal information (67) that may be sensitive to modulation via a potent intervention, and that other preprocessing procedures exist to address global "noise," we chose not to perform GSR in our main analyses. Instead, our thorough preprocessing included a draining veins regressor that other work has shown covaries with the global signal-yet is more clearly nonneuronal and therefore the more logical nuisance regressor. Regardless, we performed and reported the results of GSR in the SI Appendix, Fig.. Briefly, after conducting GSR, results remained largely consistent with those reported here in the main results section of this study and were inconsistent with GFC results previously published with LSD and psilocybin when GSR was performed. Data and analytical pipeline sharing is currently underway in an effort to resolve between-team results discrepancies. DMT increases peripheral markers of arousal, and some of our imaging findings are consistent with increases in arousal, such as decreased alpha power, DMN integrity, and increased LZ. However, the breadth and magnitude of the brain changes observed here with DMT surpass what one would expect from mere arousal. Importantly, in validation analyses, we did not find compelling associations between drowsiness ratings and between-condition effects on various imaging metrics (SI Appendix, Table). Furthermore, findings of increased delta power and associated hyperconnectivity are inconsistent with either increases in arousal or decreases in drowsiness. The current results with DMT are consistent with previous findings of altered brain function on LSD and psilocybin, and these previous studies did not consistently observe increases in markers of arousal. Nevertheless, further work is needed to parse specific psychedelic effects in the brain from mere increases in arousal or decreases in drowsiness. It is important to note that fMRI connectivity metrics are highly sensitive to head motion and while we did find that head motion was significantly larger under DMT versus placebo, analysis of subsamples comprised participants with comparable head motion across conditions revealed consistent findings with those reported in the main Results section (SI Appendix, Figs.and). Future research studies should endeavor to collect larger datasets with more participants, ideally with equivalent head motion between conditions. While this study found a significant relationship between changes in global functional connectivity induced by DMT and ratings of intense subjective effects, few correlations were found between imaging metrics and specific subjective effects (e.g., visual imagery, "entity" encounters, feelings of immersion; SI Appendix, Fig.). Future studies-combining neuroimaging with time-resolved measures of subjective experience and/or experience-sampling plus extensive within-subject data collection-could leverage improvements in data volume and quality for more nuanced "neurophenomenological" analyses. Finally, a minor component of the present study's results was its direct testing of the so-called "entropic brain hypothesis," which postulates that psychedelics elevate the entropy of spontaneous brain activity in parallel with increases in the "richness" of conscious experience (41, 47)-where richness is defined as depth of content. Here, we found clear support for this hypothesis via significant correlations between the self-rated richness of conscious experience and LZc increases (Fig.)-a useful marker of the entropy or complexity of spontaneous brain activity. In conclusion, the present multimodal, multivariate EEG-fMRI study with DMT revealed a robust dysregulating effect on activity in the brain's TOP, where 5-HT2A receptors (the main target of psychedelics) are most densely expressed. Observations of increased communication between the TOP of the cortex and the rest of the brain, could be interpreted as evidence of expanded information processing and a hyperassociative style of cognition. It is intriguing to speculate whether the magnitude of these global brain changes relates to increased plasticity (i.e., the property of being easily shaped or molded) in both a neuronal and behavioral sense. This study's results consolidate the view that psychedelics target and dysregulate developmentally and evolutionary recent cortex. Moreover, they imply that the normal functioning of this high-level cortex may be necessary for the preservation of human-specific psychological faculties, but not wakeful conscious experience itself.
Study Details
- Study Typeindividual
- Populationhumans
- Characteristicsbrain measuresplacebo controlledsingle blindrandomized
- Journal
- Compound
- Topics
- Authors